Paloma Partners’s Moleculin Biotech MBRX Stock Holding History

Paloma Partners’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1	Closed	-$34K	–	2301
2020 Q2	$34K	Buy	+1	New	+$47.4K	﹤0.01%	2015

Other funds holding MBRX

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return

Whitegate Investment Counselors Concord, New Hampshire $343M AUM 8.81% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Paloma Partners's MBRX Position: Q3 2020 in Review

Paloma Partners sold out of Moleculin Biotech (MBRX) in Q3 2020, closing a stake of 1 share — an estimated $34K sold.

Paloma Partners first reported a position in MBRX in Q2 2020 and held it in 1 quarter. The position peaked at $34K in Q2 2020. 13 funds tracked by Wall St. Rank hold MBRX as of Q3 2020.

Paloma Partners reported no remaining Moleculin Biotech position as of Q3 2020 after selling out during the quarter.
Paloma Partners sold 1 Moleculin Biotech share in Q3 2020, an estimated $34K.
Paloma Partners first reported a position in Moleculin Biotech in Q2 2020 and held it in 1 quarter.
Paloma Partners's Moleculin Biotech position peaked at $34K in Q2 2020.
13 funds tracked by Wall St. Rank held Moleculin Biotech as of Q3 2020.

Based on Paloma Partners's 13F filing for Q3 2020, filed 16 Nov 2020.